Description
Enoxacin is a fluoroquinolone antibiotic that is clinically used to treat urinary tract infections and gonorrhea; like other fluoroquinolones, enoxacin inhibits DNA gyrase and topoisomerase IV. Enoxacin displays antibacterial and anti-resorptive activities. In vivo, this compound decreases RANKL-induced JNK signaling, inhibiting osteoclast formation. Additionally, enoxacin inhibits vacuolar H+ ATPase activity, preventing bone resorption.
References
Liu X, Qu X, Wu C, et al. The effect of enoxacin on osteoclastogenesis and reduction of titanium particle-induced osteolysis via suppression of JNK signaling pathway. Biomaterials. 2014 Jul;35(22):5721-30. PMID: 24767789.
Toro EJ, Zuo J, Ostrov DA, et al. Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis. J Biol Chem. 2012 May 18;287(21):17894-904. PMID: 22474295.
Zuma AA, Cavalcanti DP, Maia MC, et al. Effect of topoisomerase inhibitors and DNA-binding drugs on the cell proliferation and ultrastructure of Trypanosoma cruzi. Int J Antimicrob Agents. 2011 May;37(5):449-56. PMID: 21292448.
Koseki N, Deguchi J, Yamashita A, et al. Establishment fo a novel experimental protocol for drug-induced seizure liability screening based on a locomotor activity assay in zebrafish. J Toxicol Sci. 2014 Aug;39(4):579-600. PMID: 25056783.